✦ LIBER ✦

Treatment of Higher-Risk Myelodysplastic Syndrome

✍ Scribed by Guillermo Garcia-Manero

Book ID: 114474425
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 856 KB
Volume: 38
Category: Article
ISSN: 0093-7754
DOI: 10.1053/j.seminoncol.2011.07.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of higher risk myelodysplastic

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

✍ Mahesh Seetharam; Alice C. Fan; Mai Tran; Liwen Xu; John P. Renschler; Dean W. F 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 395 KB

P-304 5-azacytidine in the treatment of

P-304 5-azacytidine in the treatment of Greek patients with higher-risk myelodysplastic syndromes. An overview

✍ Zervakis, K.; Diamantopoulos, P.; Papadopoulou, V.; Iliakis, T.; Mpakarakos, P.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 67 KB

A randomized study of 2 dose levels of i

A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome

✍ Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Gautam Bo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract ## BACKGROUND: Clofarabine is a nucleoside analog with activity in myeloid malignancies. Experience in myelodysplastic syndrome (MDS) is limited. ## METHODS: The goal of this study was to evaluate the activity and safety of 2 different doses (15 mg/m^2^ vs 30 mg/m^2^ daily × 5 days)

Rapid loss of response after withdrawal

Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia

✍ Voso, Maria Teresa; Breccia, Massimo; Lunghi, Monia; Poloni, Antonella; Niscola, 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

Efficacy of azacitidine compared with th

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

✍ Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Fi 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 232 KB

Efficacy of azacitidine compared with th

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

✍ Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Fi 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 232 KB

## Background: Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. in this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. ## Methods: In a phase iii, internation